01.07.2024 12:03:21 - EQS-News: CS MEDICA Stock Now Also Traded on XETRA

===
EQS-News: CS MEDICA A/S / Key word(s): Capital Markets Day
CS MEDICA Stock Now Also Traded on XETRA
2024-07-01 / 12:02 CET/CEST
The issuer is solely responsible for the content of this announcement.
The shares of CS MEDICA A/S (ISIN DK0061668225) have been listed on the Frankfurt Stock Exchange since March 2, 2023.
The company, a MedTech pioneer in the development of medical devices that benefit from bioactive CBD, has mandated the
private bank Hauck Aufhäuser Lampe to include the company's shares in Deutsche Börse AG's trading venue XETRA and
ensure continuous trading.
As of today, the 12,322,635 registered shares of the company can now also be traded via the electronic trading system
XETRA.
In the electronic trading system XETRA, Designated Sponsors provide additional liquidity by committing to place binding
bid and ask sizes (so-called quotes) in the order book for the securities they support during continuous trading and
auctions. The private bank Hauck Aufhäuser Lampe ensures higher liquidity in the stock in this way.
High-quality criteria (minimum requirements) are imposed on Designated Sponsors by Deutsche Börse AG for liquidity
provision. Thereby, the private bank Hauck Aufhäuser Lampe has achieved the highest rating from Deutsche Börse ('AA')
for years.
"By including our shares in the XETRA trading platform, we offer both existing and future shareholders an additional
trading opportunity," says Lone Henriksen, CEO of CS MEDICA A/S. "By committing to a Designated Sponsor, we aim to
further increase the liquidity of CS MEDICA stock and strengthen the free float. This should minimize the spread
between bid and ask prices."

CS MEDICA Group, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain
management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from
innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship
CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for
both human and veterinary health globally.

CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative
substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation,
science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The
company ensures robust research, development, manufacturing, compliance, data insights, and commercialization
processes.
The group's shares are traded on the stock exchanges and trading platforms in Frankfurt, Munich, Stuttgart, and XETRA,
as well as on the Spotlight Stock Market in Stockholm under ISIN DK0061668225.

2024-07-01 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com  
Language:     English 
Company:      CS MEDICA A/S 

Indiakaj 10,2
2100 Copenhagen
Denmark
Phone:        +45 70707337 
E-mail:       info@cs-medica.com 
Internet:     https://www.cs-medica.com 
ISIN:         DK0061668225 
WKN:          A3CYEQ 
Listed:       Regulated Unofficial Market in Frankfurt, Munich, Stuttgart 
EQS News ID:  1936153 


End of News EQS News Service
===
1936153 2024-07-01 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1936153&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

END) Dow Jones Newswires

July 01, 2024 06:03 ET (10:03 GMT)
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
CS MEDICA A/S DK -,065 A3CYEQ Xetra 0,395 11.07.24 17:35:43 +0,010 +2,60% 0,000 0,000 0,395 0,385

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH